Myovant Stock Today

MYOV -  USA Stock  

USD 20.28  0.22  1.07%

Myovant Sciences is selling for under 20.28 as of the 27th of July 2021; that is -1.07 percent decrease since the beginning of the trading day. The stock's lowest day price was 19.78. Myovant Sciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Myovant Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2021 and ending today, the 27th of July 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 93

Myovant Sciences Stock Profile

The upcoming quarterly report is expected on the 28th of July 2021. Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people. more on Myovant Sciences
Myovant Sciences has a very high chance of going through financial distress in the upcoming years
Myovant Sciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 59.32 M. Net Loss for the year was (255.13 M) with loss before overhead, payroll, taxes, and interest of (79.36 M).
Myovant Sciences has a poor financial position based on the latest SEC disclosures
About 60.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.equities.com: Myovant Sciences Ltd gains 2.71 percent for July 21 - Equities.com
Myovant Sciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Myovant Sciences SEC Filings
Myovant Sciences SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameMyovant Sciences
Chairman of the BoardMyrtle Potter  (View All)
Average Analyst Recommendation
Analysts covering Myovant Sciences report their recommendations after researching Myovant Sciences' financial statements, talking to executives and customers, or listening in on Myovant Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Myovant Sciences. The Myovant consensus assessment is calculated by taking the average forecast from all of the analysts covering Myovant Sciences.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Myovant Sciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Myovant Sciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares88.1 M90 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted88.1 M90 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations399.9 M370.6 M
Significantly Up
Increasing
Slightly volatile
Total Assets782.3 M725 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities1.2 B1.1 B
Significantly Up
Increasing
Slightly volatile
Current Assets760.3 M704.6 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities303.6 M281.3 M
Significantly Up
Increasing
Slightly volatile
Total Debt398.9 M369.7 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.120.12
Steady
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Myovant Sciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Myovant Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Myovant Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Myovant Sciences' financial leverage. It provides some insight into what part of Myovant Sciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Myovant Sciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Myovant Sciences deploys its capital and how much of that capital is borrowed.
Liquidity
Myovant Sciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 369.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 2.46, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

399.89 MillionShare
Myovant Sciences (MYOV) is traded on New York Stock Exchange in USA. It is located in 11-12 St. James’s Square and employs 407 people. Myovant Sciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Myovant Sciences's market, we take the total number of its shares issued and multiply it by Myovant Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Myovant Sciences conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 91.48 M outstanding shares of which 3.03 M shares are now shorted by private and institutional investors with about 4.19 trading days to cover. Myovant Sciences currently holds about 684.93 M in cash with 370.63 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.49.
Check Myovant Sciences Probability Of Bankruptcy
Ownership
Myovant Sciences maintains a total of ninety-one million four hundred eighty thousand outstanding shares. Myovant Sciences secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 60.22 % of Myovant Sciences outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Myovant Ownership Details

Myovant Stock Price Odds Analysis

What are Myovant Sciences' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Myovant Sciences jumping above the current price in 90 days from now is about 79.55%. The Myovant Sciences probability density function shows the probability of Myovant Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Myovant Sciences has a beta of -0.2666. This indicates as returns on benchmark increase, returns on holding Myovant Sciences are expected to decrease at a much lower rate. During the bear market, however, Myovant Sciences is likely to outperform the market. Additionally, the company has an alpha of 0.1172, implying that it can generate a 0.12 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 20.28HorizonTargetOdds Up 20.28 
20.32%90 days
 20.28 
79.55%
Based on a normal probability distribution, the odds of Myovant Sciences to move above the current price in 90 days from now is about 79.55 (This Myovant Sciences probability density function shows the probability of Myovant Stock to fall within a particular range of prices over 90 days) .

Myovant Sciences Historical Income Statement

Myovant Sciences Income Statement is one of the three primary financial statements used for reporting Myovant's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Myovant Sciences revenue and expense. Myovant Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Myovant Sciences Research and Development Expense is fairly stable at the moment as compared to the past year. Myovant Sciences reported Research and Development Expense of 136.71 Million in 2020. Selling General and Administrative Expense is likely to climb to about 195.7 M in 2021, whereas Earning Before Interest and Taxes EBIT is likely to drop (263.7 M) in 2021. View More Fundamentals

Myovant Stock Against Markets

Picking the right benchmark for Myovant Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Myovant Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Myovant Sciences is critical whether you are bullish or bearish towards Myovant Sciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Myovant Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Myovant Sciences Corporate Directors

Myovant Sciences corporate directors refer to members of a Myovant Sciences board of directors. The board of directors generally takes responsibility for the Myovant Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Myovant Sciences' board members must vote for the resolution. The Myovant Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Keith Manchester - DirectorProfile
Mark Altmeyer - Independent DirectorProfile
Frank Torti - DirectorProfile
Vivek Ramaswamy - DirectorProfile
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
CEO Directory
Screen CEOs from public companies around the world
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.